Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Corporate Story
Corporate Story
CORE PRINCIPLE / Our Commitment
CORE PRINCIPLE / Our Commitment
Our Values
Our Values
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP & Santen 2030
Medium-term Management Plan
Santen 2030
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Quality Compliance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Our Sustainability Commitment
Our Sustainability Commitment
Sustainability at Santen
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2017
IR News
2017 IR News
RSS
IR News
12.21.2017
Santen Receives Complete Response Letter from U.S. FDA for Intravitreal Sirolimus (DE-109)
11.27.2017
Santen Files for Manufacturing and Marketing Approval of Glaucoma and Ocular Hypertension Drug Candidate DE-117 (JAN: Omidenepag Isopropyl)
11.01.2017
Santen Reports the 2nd Quarter Fiscal 2017 Consolidated Performance
11.01.2017
Santen Announces Approval of Diquas for the Treatment of Dry Eye in China
09.19.2017
Santen Selected as a Member of Dow Jones Sustainability Asia Pacific Index, an Index for Socially Responsible Investment
09.01.2017
Notice on Details of Subscription Rights to New Shares(Stock Options for Stock-Linked Remuneration)
08.22.2017
Corporate Governance Report
08.01.2017
Santen Reports the 1st Quarter Fiscal 2017 Consolidated Performance
08.01.2017
Santen to Grant Subscription Rights to New Shares as Stock Options for Stock-Linked Remuneration
07.26.2017
Santen Receives Positive CHMP Opinion in Europe for Ciclosporin eye drops for the Treatment of Paediatric Patients with Severe Vernal Keratoconjunctivitis
07.26.2017
Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration
07.03.2017
(Correction) Corporate Governance Report
06.30.2017
Corporate Governance Report
05.10.2017
Notice of Board of Director and Corporate Auditor Nominations
05.10.2017
Santen Reports Fiscal 2016 Consolidated Performance
04.25.2017
Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Intravitreal Sirolimus (DE-109) in the Treatment of NIU-PS
04.07.2017
Santen Announces Strategic Investment in Regenerative Patch Technologies LLC
03.16.2017
Santen and Japan Blind Football Association (JBFA) Enter Partnership
03.15.2017
Notice of Corporate Officer Appointments
03.02.2017
SANTEN AND SINGAPORE EYE RESEARCH INSTITUTE (SERI) ANNOUNCE AN EXPANDED RELATIONSHIP INCLUDING THE CREATION OF A NEW JOINT LABORATORY TO DEVELOP NOVEL OPHTHALMIC THERAPEUTICS, DIAGNOSTICS AND DEVICES
02.07.2017
Santen Reports the 3rd Quarter Fiscal 2016 Consolidated Performance
News Archive
